Incidence of treatment-related adverse events
| Any-grade in ≥ 5% of patients or any grade 3 TRAEs | N = 51 | |
|---|---|---|
| Any graden (%) | Grade 3n (%) | |
| Patients with ≥1 event | 39 (76.5) | 4 (7.8) |
| Infusion-related reaction | 15 (29.4) | 0 |
| Fatigue | 9 (17.6) | 0 |
| Chills | 6 (11.8) | 0 |
| Diarrhea | 5 (9.8) | 0 |
| Dysgeusia | 4 (7.8) | 0 |
| Pyrexia | 4 (7.8) | 0 |
| Aspartate aminotransferase increased | 3 (5.9) | 0 |
| Dry mouth | 3 (5.9) | 0 |
| Nausea | 2 (3.9) | 1 (2.0) |
| Gamma-glutamyltransferase increased | 1 (2.0) | 1 (2.0) |
| Hypokalemia | 1 (2.0) | 1 (2.0) |
| Lipase increased | 1 (2.0) | 1 (2.0) |
| All immune-related TRAEs | ||
| Patients with ≥1 event | 5 (9.8) | 0 |
| Hypothyroidism | 2 (3.9) | 0 |
| Pneumonitis | 2 (3.9) | 0 |
| Hyperthyroidism | 1 (2.0) | 0 |
| Sarcoidosis | 1 (2.0) | 0 |
| Vitiligo | 1 (2.0) | 0 |